Drug
Ro7269162
Ro7269162: highest development phase Phase 2, developed by Roche. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Roche
Trials
| Drug | Phase | Indication |
|---|---|---|
| RO7269162 NCT06402838 | Phase 2 | Alzheimer's Disease |
Latest
No recent events.
Follow Ro7269162 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.